Search the Newsreel

Tango Therapeutics, Inc. (TNGX) Stock Price, News, Quote & History

This article provides comprehensive financial information for Tango Therapeutics, Inc. (TNGX), including its current stock price, historical data, recent news, and analyst ratings. It details the company's focus on precision oncology and its drug development pipeline. The report also includes performance metrics, earnings trends, …

TNGX: Tango Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides an overview of Tango Therapeutics Inc (TNGX), including its latest stock price, market capitalization, key financial metrics, and upcoming earnings date. It also features recent news headlines related to TNGX and discussions on other trending stocks like SPY, HIMS, and NOW, …

CCORF Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $46

CCORF has reiterated its Buy rating for Tango Therapeutics (TNGX.US), maintaining its target price at $46. This reflects a continued positive outlook on the company's stock performance by the firm.

Tango Therapeutics Inc (TNGX) Institutional Confidence

Tango Therapeutics Inc (TNGX) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 123.32%, a significant quarter-over-quarter increase of 24.30%. Steven Cohen is the largest institutional shareholder, holding 568.45K shares.

Mizuho Raises Price Target on Tango Therapeutics to $40 From $36, Keeps Outperform Rating

Mizuho has increased its price target for Tango Therapeutics (NASDAQ: TNGX) to $40, up from the previous $36, while maintaining an Outperform rating. This adjustment suggests a positive outlook on the company's future performance and stock valuation.

TNGX Maintained by Mizuho -- Price Target Raised to $40.00

Mizuho has maintained an "Outperform" rating for Tango Therapeutics (TNGX) and increased its price target to $40.00, reflecting optimism about the company's growth in cancer therapies. Despite the positive analyst sentiment, GuruFocus indicates that TNGX is significantly overvalued, trading at 196.2% above its intrinsic …

Mizuho raises Tango Therapeutics stock price target on combo data

Mizuho has increased its price target for Tango Therapeutics (NASDAQ:TNGX) to $40 from $36, maintaining an Outperform rating, based on promising new data for its drug combinations in pancreatic cancer. This comes amidst recent positive analyst revisions and a significant stock offering, with the …

Tango Therapeutics (NASDAQ:TNGX) Stock Price Up 6.1% - Time to Buy?

This Veracyte Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

A Piper Sandler analyst has initiated coverage on Veracyte Inc. (NASDAQ: VCYT) with an Overweight rating and a $66 price target. This report also details four other analyst initiations for Wednesday, covering companies like Unusual Machines Inc., Deep Fission, Inc., Lantronix Inc., and Tango …

J.P. Morgan Initiates Tango Therapeutics(TNGX.US) With Buy Rating, Announces Target Price $46

J.P. Morgan has initiated coverage on Tango Therapeutics (TNGX.US) with a 'Buy' rating. The investment bank has also set a target price of $46 for the company's stock.

TNGX Initiates Coverage On JP Morgan -- Rating Set to Overweight

JP Morgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and a price target of $46.00. Despite this positive analyst recommendation, GuruFocus indicates that TNGX is significantly overvalued by 202.9%, with a GF Value of $9.79 against a current trading price …

JPMorgan initiates Tango Therapeutics stock at Overweight By Investing.com

JPMorgan initiated coverage on Tango Therapeutics Inc. (NASDAQ:TNGX) with an Overweight rating and a $46.00 price target, despite the stock's significant surge and being considered overvalued by InvestingPro analysis. The firm highlighted Tango's progress with its lead PRMT5 inhibitor vopimetostat and advancing combination trials …

JPMorgan Initiates Coverage on Tango Therapeutics With Overweight Rating, $46 Price Target

JPMorgan has initiated coverage on Tango Therapeutics (TNGX) with an Overweight rating and set a price target of $46. This positive outlook follows several recent developments for Tango Therapeutics, including its inclusion in various Russell indices. The company specializes in developing precision medicines for …